Oncolytics Biotech Inc T.ONC

Gilead's ADC Trodelvy comes up short in ER+/Her2- BC

[Noteable]

June 04, 2022 - Reorted at ASCO the Gilead's ADC sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer was being trialed in ER+/HER2-NEGATIVE breast cancer but comes up short in demonstrating overall survival (OS). This shortfall places ONCY's oncolytic virus pelareorep in an even stronger position when combined with bispecifics.

[Noteable]

Patients who received Trodelvy went a median 5.5 months without tumor progression, a mere 1.5-month improvement over the median four months registered in the chemotherapy arm of the trial. And that small difference throws some doubt on the drugs value in this key potential market expansion opportunity. Advantage ONCY's pelareorep.

[Noteable]

Gilead has tagged Trodelvy as a cornerstone of its ambition to have a third of its revenue from oncology by 2030. The TROP2-targeted antibody-drug conjugate was the centerpiece of Gileads $21 billion acquisition of Immunomedics in 2020.

[Noteable]

Historically, only drugs that indirectly affect tumors through the immune system have succeeded in achieving a wider improvement in patient survival after a modest disease progression effect, and Trodelvy doesnt work that way. This once again points to pelareorep's mechanism of action which is to stimulate both the innate and adaptive immune systems while overcoming a hostile immunosuppressive

[canadafan]

thank you notable for your detailed & broad research. Indicators showing bolder & broader opportunities for Pela.  Some points, require a bit of comparison- analysis. To accomplish one needs to understand not only Onc ( Pelareorep), but the broader cancer therapy world in general. The recent post, re the Pfizer trial failure, in- directly is a boost for Pela & ONC

[fasttrack5]

The recent post, re the Pfizer trial failure, in- directly is a boost for Pela & ONC. indications, Pela can do what that trial failed at.....making Onc a great option for Pfizer. hopefully sooner than later canadafan should be a great adding on/buying opportunity. So hanging on waiting impatiently:)

[Noteable]

Review this thread since I already posted that patients who received Trodelvy went a median 5.5 months without tumor progression, a mere 1.5-month improvement over the median four months registered in the chemotherapy arm of the trial. And that small difference throws some doubt on the drugs value in this key potential market expansion opportunity. Advantage ONCY's pelareorep.

[Noteable]

I also posted this - Historically, only drugs that indirectly affect tumors through the immune system have succeeded in achieving a wider improvement in patient survival after a modest disease progression effect, and Trodelvy doesn't work that way. This once again points to pelareorep's mechanism of action which is to stimulate both the innate and adaptive immune systems while

[Noteable]

August 16, 2022 - When Gilead Sciences acquired Immunomedics in 2020 for USD$ 21 Billion, another company owned certain rights to the deal's crown jewel Trodelvy. Now, Gilead thinks it’s time to take it back.   Gilead is shelling out $280 million upfront to gain Trodelvy rights from Chinese company Everest Medicines in certain Asian territories including China, South Korea

[Noteable]

One area where Trodelvy could put up a fight against Enhertu is tolerability, according to SVB analysts. Enhertu is known to cause interstitial lung disease, and that could be problematic for some patients in earlier lines of treatment. A roughly 10% case rate of interstitial lung disease suggests that Enhertu may have a hard time getting into early-stage disease and may continue to be